跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 29,116 条关于
“Actuate-1801”
全部
29,116
临床试验
27,397
药物
1,005
机构
8
资讯
706
去年
Actuate Therapeutics' Elraglusib Shows Promise in Pancreatic Cancer as IPO Lock-up Expires
去年
Elraglusib Receives EMA Orphan Drug Designation for Pancreatic Cancer Treatment
去年
Elraglusib Plus Chemotherapy Shows Promise in Metastatic Pancreatic Cancer
3年前
Elraglusib Receives FDA Orphan Drug Designation for Pancreatic Cancer Treatment
去年
Appili Therapeutics Advances ATI-1801 Development for Cutaneous Leishmaniasis with FDA Alignment
去年
Actuate Therapeutics and Lantern Pharma Collaborate on AI-Driven Elraglusib Development
2个月前
Sareum Completes Dosing in Phase 2-Enabling Toxicology Programme for TYK2/JAK1 Inhibitor SDC-1801
去年
Actuate Therapeutics Reports Significant Survival Improvement in Metastatic Pancreatic Cancer Phase 2 Trial
11个月前
Sareum Halts SDC-1801 Toxicology Study Due to Animal Welfare Concerns, Phase 2 Psoriasis Trial Delayed
11个月前
Light Chain Bioscience Reports Promising Survival Data for NI-1801 Bispecific Antibody in Platinum-Resistant Ovarian Cancer
第 1 页,共 71 页
上一页
下一页